Grown Rogue International (GRUSF) Cash & Equivalents (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Cash & Equivalents came in at $13.7 million in Q1 2026, up 106.32% year-on-year from $6.6 million in Q1 2025, and up 20.48% quarter-over-quarter from $11.4 million in Q4 2025.
Grown Rogue International (GRUSF) Cash & Equivalents (2009 - 2026) Analysis & Trends
Grown Rogue International's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $13.7 million for Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 106.32% year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a 106.32% increase from a year earlier, with the FY2025 full-year figure at $11.4 million, up 131.24% from the prior year.
- Cash & Equivalents advanced to $13.7 million in Q1 2026 per GRUSF's latest filing, from $11.4 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $9252242000.0 billion in Q2 2025 and bottomed at $1.19 in Q4 2022.
- The 5-year median for Cash & Equivalents is $5.9 million (2024), against an average of $578265943.4 billion.
- Across the five-year window, Cash & Equivalents tumbled 100.0% in 2022 and soared 168236167789635.1% in 2025, its largest moves.
- Year by year, Cash & Equivalents stood at $1.19 in 2022, then jumped by 419534249.68% to $5.0 million in 2023, then plunged by 32.94% to $3.4 million in 2024, then soared by 239.28% to $11.4 million in 2025, then gained by 20.48% to $13.7 million in 2026.
- Per Business Quant, the three latest GRUSF Cash & Equivalents figures stand at $13.7 million (Q1 2026), $11.4 million (Q4 2025), and $13094.1 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.70 Mn |
| Dec 31, 2025 | 11.37 Mn |
| Sep 30, 2025 | 13,094.09 Bn |
| Jun 30, 2025 | 9,252,242,000.00 Bn |
| Mar 31, 2025 | 6.64 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 5.50 Mn |
| Mar 31, 2024 | 7.02 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Oct 31, 2023 | 6.53 Mn |
| Jul 31, 2023 | 6.36 Mn |
| Apr 30, 2023 | 3.79 Mn |
| Jan 31, 2023 | 1.58 Mn |
| Oct 31, 2022 | 1.19 |
| Jan 31, 2022 | 1.11 Mn |
| Oct 31, 2021 | 886,143.93 |
| Jul 31, 2021 | 217,788.00 |
| Apr 30, 2021 | 1.72 Mn |
| Jan 31, 2021 | 1.28 Mn |